Figure 1.

Multivariable Cox regression between tertiles of uric acid at baseline (<309.30 μmol/L, 309.30 to <387.21 μmol/L, and ≥387.21 μmol/L) for cardiovascular (CV) and kidney outcomes in the placebo and empagliflozin treatment groups. *Cox regression analysis was used to derive the hazard ratio (HR) and 95% confidence interval (CI). Cox regression model included age, sex, baseline body mass index (BMI; categorical), baseline glycated haemoglobin (HbA1c; categorical), baseline estimated glomerular filtration rate (eGFR; categorical), region, baseline use of diuretics, baseline anti‐gout medication, baseline heart failure (HF), and tertiles of baseline uric acid. ^†Excludes fatal stroke. 3P‐MACE, three‐point major adverse CV events; ACM, all‐cause mortality; HHF, hospitalization for heart failure